According to a recent LinkedIn post from Xeltis, the company’s aXess hemodialysis conduit was prominently featured at the 11th “Vascular Access” Project Group Conference of the Italian Society of Nephrology and the 5th Vascular Access Society Italian Chapter meeting in Apulia. The post notes that more than 200 healthcare professionals attended, providing a forum for discussion of vascular access innovations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights two clinical presentations focused on aXess, including an overview of Xeltis’ technology and 12‑month results from the aXess Pivotal Study, which reportedly generated strong interest. A second presentation from the Policlinico of Bari shared outcomes from 24 patients in the pivotal study, with the post indicating encouraging results and favorable comparisons versus ePTFE grafts at the same institution.
As shared in the post, the Policlinico of Bari team received a “Best Poster Award” for a study suggesting infection‑free hemodialysis access with high patency using Xeltis’ bioresorbable aXess conduits. The recognition of clinical partners and emphasis on pivotal‑study progress suggest Xeltis is building third‑party clinical validation, which could support future regulatory pathways and reimbursement discussions.
For investors, the focus on pivotal‑study outcomes and external recognition may indicate advancing clinical momentum in the hemodialysis vascular access market, a segment where infection and patency remain key unmet needs. If longer‑term data continue to be favorable and translate into regulatory approvals, Xeltis could strengthen its competitive position versus traditional ePTFE graft providers and potentially expand its addressable market in renal care and vascular access devices.